CN105636940B - 制备嘧啶中间物的方法 - Google Patents

制备嘧啶中间物的方法 Download PDF

Info

Publication number
CN105636940B
CN105636940B CN201480039832.2A CN201480039832A CN105636940B CN 105636940 B CN105636940 B CN 105636940B CN 201480039832 A CN201480039832 A CN 201480039832A CN 105636940 B CN105636940 B CN 105636940B
Authority
CN
China
Prior art keywords
compound
formula
ethylene glycol
mixture
methyl isobutyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480039832.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN105636940A (zh
Inventor
斯蒂芬·阿贝勒
雅克-亚丽克西斯·富内尔
伊凡·申德尔霍尔兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CN105636940A publication Critical patent/CN105636940A/zh
Application granted granted Critical
Publication of CN105636940B publication Critical patent/CN105636940B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Detergent Compositions (AREA)
  • Magnetic Heads (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Manufacturing Cores, Coils, And Magnets (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201480039832.2A 2013-07-12 2014-07-11 制备嘧啶中间物的方法 Active CN105636940B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13176374.0 2013-07-12
EP13176374 2013-07-12
PCT/EP2014/064904 WO2015004265A1 (en) 2013-07-12 2014-07-11 Process for preparing a pyrimidine intermediate

Publications (2)

Publication Number Publication Date
CN105636940A CN105636940A (zh) 2016-06-01
CN105636940B true CN105636940B (zh) 2018-02-27

Family

ID=48790244

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480039832.2A Active CN105636940B (zh) 2013-07-12 2014-07-11 制备嘧啶中间物的方法

Country Status (17)

Country Link
US (1) US9556125B2 (enExample)
EP (1) EP3019479B1 (enExample)
JP (1) JP6375374B2 (enExample)
KR (1) KR102305298B1 (enExample)
CN (1) CN105636940B (enExample)
AR (1) AR096865A1 (enExample)
CA (1) CA2915736C (enExample)
DK (1) DK3019479T3 (enExample)
ES (1) ES2636937T3 (enExample)
HR (1) HRP20171166T1 (enExample)
HU (1) HUE034071T2 (enExample)
IL (1) IL243477B (enExample)
MX (1) MX360768B (enExample)
PL (1) PL3019479T3 (enExample)
PT (1) PT3019479T (enExample)
TW (1) TWI643848B (enExample)
WO (1) WO2015004265A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA201605808B (en) 2015-08-26 2017-08-30 Cipla Ltd Process for preparing an endothelin receptor antagonist
CN105461638A (zh) * 2015-12-10 2016-04-06 合肥久诺医药科技有限公司 一种马西替坦晶型及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1524079A (zh) * 2000-12-18 2004-08-25 ������˹ҩƷ��˾ 新颖的磺酰胺类化合物及其作为内皮素受体拮抗剂的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103724281A (zh) * 2013-12-03 2014-04-16 镇江圣安医药有限公司 N-[5-(4-溴苯基)-6-[2-[(5-溴-2-嘧啶基)氧基]乙氧基]-4-嘧啶基]-n′-丙基磺酰胺的新型衍生物及其应用
CN103819411A (zh) * 2014-03-14 2014-05-28 成都克莱蒙医药科技有限公司 一种马西替坦中间体新的制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1524079A (zh) * 2000-12-18 2004-08-25 ������˹ҩƷ��˾ 新颖的磺酰胺类化合物及其作为内皮素受体拮抗剂的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The Discovery of N‑[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]‑N′‑propylsulfamide (Macitentan), an Orally Active, Potent Dual Endothelin Receptor Antagonist;Bolli et al.;《Journal of Medicinal Chemistry》;20120803;第55卷;第7849-7861页 *

Also Published As

Publication number Publication date
EP3019479B1 (en) 2017-05-10
KR20160030972A (ko) 2016-03-21
KR102305298B1 (ko) 2021-09-27
US9556125B2 (en) 2017-01-31
JP2016525094A (ja) 2016-08-22
MX2016000386A (es) 2016-04-29
IL243477B (en) 2018-06-28
PL3019479T3 (pl) 2017-10-31
US20160145215A1 (en) 2016-05-26
TWI643848B (zh) 2018-12-11
HRP20171166T1 (hr) 2017-10-06
DK3019479T3 (en) 2017-07-17
WO2015004265A1 (en) 2015-01-15
MX360768B (es) 2018-11-15
CA2915736C (en) 2021-07-27
EP3019479A1 (en) 2016-05-18
AR096865A1 (es) 2016-02-03
ES2636937T3 (es) 2017-10-10
HUE034071T2 (en) 2018-01-29
CA2915736A1 (en) 2015-01-15
JP6375374B2 (ja) 2018-08-15
CN105636940A (zh) 2016-06-01
TW201536759A (zh) 2015-10-01
PT3019479T (pt) 2017-08-11

Similar Documents

Publication Publication Date Title
EP3214082B1 (en) Process for manufacturing pyrimidine sulfamide derivatives
CA2900911C (en) Preparation of pyrimidine intermediates useful for the manufacture of macitentan
CA3005738C (en) 4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1h-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile and processes of preparation
EP3377475A1 (en) 4-((6-2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1h-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile and processes of preparation
CN105636940B (zh) 制备嘧啶中间物的方法
CN102171212A (zh) 作为合成中间体的噻唑基吡唑并嘧啶化合物及相关的合成方法
CN101627041A (zh) 合成(3-烷基-5-哌啶-1-基-3,3a-二氢-吡唑并[1,5-a]嘧啶-7-基)-氨基衍生物和中间体的方法和中间体
HK40044947B (zh) 氨基嘧啶的制备方法和其中间体
KR20170044166A (ko) 3-페닐/헤테로아릴-6-페녹시-8-알킬아미노-이미다조[1,2-b]피리다진 유도체의 제조 방법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant